ETNB Valuation

89Bio Inc

Add to Watchlist

Advanced Chart

14.950

+0.11(0.741%)1D

ETNB Relative Valuation

ETNB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ETNB is overvalued; if below, it's undervalued.

Historical Valuation

89Bio Inc (ETNB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.35. The fair price of 89Bio Inc (ETNB) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：14.95

Fair

-4.75

Trailing

Forward

-2.66

EV/EBITDA

89Bio Inc. (ETNB) has a current EV/EBITDA of -2.66. The 5-year average EV/EBITDA is -2.09. The thresholds are as follows: Strongly Undervalued below -5.33, Undervalued between -5.33 and -3.71, Fairly Valued between -0.48 and -3.71, Overvalued between -0.48 and 1.14, and Strongly Overvalued above 1.14. The current Forward EV/EBITDA of -2.66 falls within the Historic Trend Line -Fairly Valued range.

-2.47

EV/EBIT

89Bio Inc. (ETNB) has a current EV/EBIT of -2.47. The 5-year average EV/EBIT is -2.13. The thresholds are as follows: Strongly Undervalued below -5.47, Undervalued between -5.47 and -3.80, Fairly Valued between -0.45 and -3.80, Overvalued between -0.45 and 1.22, and Strongly Overvalued above 1.22. The current Forward EV/EBIT of -2.47 falls within the Historic Trend Line -Fairly Valued range.

0.00

89Bio Inc. (ETNB) has a current PS of 0.00. The 5-year average PS is 491.32. The thresholds are as follows: Strongly Undervalued below -1693.37, Undervalued between -1693.37 and -601.03, Fairly Valued between 1583.66 and -601.03, Overvalued between 1583.66 and 2676.00, and Strongly Overvalued above 2676.00. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-4.36

P/OCF

89Bio Inc. (ETNB) has a current P/OCF of -4.36. The 5-year average P/OCF is -4.13. The thresholds are as follows: Strongly Undervalued below -8.55, Undervalued between -8.55 and -6.34, Fairly Valued between -1.93 and -6.34, Overvalued between -1.93 and 0.28, and Strongly Overvalued above 0.28. The current Forward P/OCF of -4.36 falls within the Historic Trend Line -Fairly Valued range.

-4.63

P/FCF

89Bio Inc. (ETNB) has a current P/FCF of -4.63. The 5-year average P/FCF is -4.42. The thresholds are as follows: Strongly Undervalued below -8.84, Undervalued between -8.84 and -6.63, Fairly Valued between -2.21 and -6.63, Overvalued between -2.21 and -0.00, and Strongly Overvalued above -0.00. The current Forward P/FCF of -4.63 falls within the Historic Trend Line -Fairly Valued range.

89Bio Inc (ETNB) has a current Price-to-Book (P/B) ratio of 2.55. Compared to its 3-year average P/B ratio of 2.38 , the current P/B ratio is approximately 6.91% higher. Relative to its 5-year average P/B ratio of 2.11, the current P/B ratio is about 20.56% higher. 89Bio Inc (ETNB) has a Forward Free Cash Flow (FCF) yield of approximately -26.73%. Compared to its 3-year average FCF yield of -17.87%, the current FCF yield is approximately 49.55% lower. Relative to its 5-year average FCF yield of -28.75% , the current FCF yield is about -7.05% lower.

2.55

P/B

Median3y

2.38

Median5y

2.11

-26.73

FCF Yield

Median3y

-17.87

Median5y

-28.75

Competitors Valuation Multiple

The average P/S ratio for ETNB's competitors is 15.71, providing a benchmark for relative valuation. 89Bio Inc Corp (ETNB) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ARS Pharmaceuticals Inc

Arcutis Biotherapeutics Inc

Ocular Therapeutix Inc

Centessa Pharmaceuticals PLC

26.70

3.59B

Performance Decomposition

Market capitalization of ETNB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ETNB in the past 1 year is driven by Unknown.